Researchers tested a new combination of two cancer drugs — sacituzumab govitecan and pembrolizumab — as the first treatment for patients with PD-L1-positive advanced TNBC. PD-L1 is a protein on some cancer cells that interacts with the immune system.
Triple-negative breast cancer, or TNBC, is one of the most aggressive forms of breast cancer. It’s called “triple negative” because the cancer cells lack three common receptors — estrogen, progesterone, and HER2 — that some other breast cancers have.
Triple-negative breast cancer, or TNBC, is one of the most aggressive forms of breast cancer. It’s called “triple negative” because the cancer cells lack three common receptors — estrogen, progesterone, and HER2 — that some other breast cancers have. That matters because most targeted therapies work by attaching to one of those receptors.
GLP-1 medicines are best known for treating type 2 diabetes and helping with weight loss. Now, researchers are studying whether these medications may have other health effects, including a possible link to lower breast cancer risk. A new study looked at women who had breast imaging and found that those prescribed GLP-1 medicines had a lower rate of breast cancer...
A new clinical trial suggests that a low daily dose of endoxifen may help lower breast cancer risk by reducing breast density. Breast density is an important risk factor for breast cancer and can also make tumors harder to detect on mammograms. In this study, researchers found that even small doses of endoxifen led to meaningful reductions in breast density with manageable side effects.